Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Route of nutrition and muscle wasting after oesophagectomy
2023-507649-27-00Phase 4Authorised
- Sponsor
- Aarhus University
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of SmofKabiven Peripheral in esophageal cancer (2 arms), sponsored by Aarhus University. Primary endpoint: Mean difference in muscle size assessed by CT-scan. Planned start Jan 2024; status: authorised.
02
Drugs
SmofKabiven Peripheral
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on 2023-507649-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507649-27-00.